Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMetaVia Inc.

MetaVia Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.41 USD 0.32 ( 29.36%)
Last update at 2026-11-06T21:02:00Z
VOLUME
917964
Market Cap
10.41M

Momentum Score

…

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.09
Low
1.44
High
52 Week Price Range
0.97
Low
14.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.09
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-175.68%
Net Debt
-10.07M
ROCE
-20.44%
Diluted EPS TTM
-2.40

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.97M -27.59M -12.47M -13.97M -15.28M
Net income -12.97M -27.59M -12.47M -13.97M -15.28M
Selling general administrative 6.91M 7.26M 6.73M 8.64M 8.75M
Gross profit -0.02M -0.02M -0.01M -0.03M -0.07M
Reconciled depreciation 0.02M 0.02M 0.01M 0.02M 0.05M
Ebit -12.97M -27.59M -12.47M -11.78M -15.28M
Ebitda -12.95M -27.57M -12.46M -11.76M -15.24M
Depreciation and amortization 0.02M 0.02M 0.01M 0.02M 0.05M
Operating income -13.71M -28.81M -15.89M -19.63M -15.30M
Other operating expenses 13.71M 28.81M 15.89M 19.63M 15.30M
Interest expense - - 0.00M 2.19M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.51M 0.92M 0.46M 0.00M 0.01M
Net interest income 0.51M 0.92M 0.46M -2.19M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 13.69M 28.81M 15.89M 19.63M 15.30M
Cost of revenue 0.02M 0.02M 0.01M 0.03M 0.07M
Total other income expense net 0.73M 1.22M 3.42M 5.66M 0.01M
Net income from continuing ops -12.97M -27.59M -12.47M -13.97M -15.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 69.12M 16.26M 22.78M 33.53M 16.80M
Other current assets 0.60M 0.06M 0.08M 0.17M 0.20M
Total liab 63.79M 8.33M 6.10M 11.78M 2.20M
Total stockholder equity 5.33M 7.93M 16.68M 21.75M 14.60M
Other current liab 4.52M 4.31M 5.07M 11.08M 1.30M
Common stock 0.00M 0.01M 0.01M 0.03M 0.00M
Capital stock 0.00M 0.01M 0.01M 0.03M 0.00M
Retained earnings -148.83M -135.86M -108.27M -95.80M -81.83M
Cash 10.28M 16.02M 22.43M 33.36M 16.39M
Total current liabilities 5.65M 8.27M 5.96M 11.78M 2.16M
Net debt -10.07M -15.88M -22.23M -33.36M -16.32M
Short term debt 0.07M 0.08M 0.07M - 0.03M
Short long term debt total 0.21M 0.14M 0.20M - 0.07M
Other stockholder equity 154.16M 143.78M 124.94M 117.52M 96.42M
Total current assets 10.88M 16.07M 22.51M 33.53M 16.58M
Accounts payable 1.06M 3.88M 0.82M 0.71M 0.83M
Accumulated other comprehensive income - - - - 0.00M
Non currrent assets other 0.02M 0.02M 0.02M - -
Non current assets total 58.25M 0.19M 0.27M 0.00M 0.21M
Capital lease obligations 0.21M 0.14M 0.20M 0.00M 0.07M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01M -0.05M 0.01M -0.59M
Total cashflows from investing activities -0.00M -0.01M -0.05M 0.01M -0.59M
Total cash from financing activities 9.96M 18.30M -0.08M 28.68M 22.03M
Net income -12.97M -27.59M -12.47M -13.97M -15.28M
Change in cash -5.74M -6.42M -10.93M 16.98M 6.30M
Begin period cash flow 16.02M 22.43M 33.36M 16.39M 10.09M
End period cash flow 10.28M 16.02M 22.43M 33.36M 16.39M
Total cash from operating activities -15.70M -24.71M -10.80M -11.71M -15.13M
Issuance of capital stock 11.21M 20.00M 0.00M 32.25M 24.00M
Depreciation 0.02M 0.02M 0.01M 0.02M 0.05M
Other cashflows from investing activities - - - 0.01M -0.58M
Other cashflows from financing activities -0.01M -1.70M -0.08M -3.57M -1.97M
Capital expenditures 0.00M 0.01M 0.05M 0.00M 0.00M
Change in working capital -2.93M 2.62M 4.40M -1.17M -0.58M
Stock based compensation 0.41M 0.54M 0.22M 0.85M 0.66M
Other non cash items -0.23M -0.29M -2.95M 2.55M 0.02M
Free cash flow -15.70M -24.72M -10.85M -11.71M -15.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MTVA
MetaVia Inc.		 0.32
29.36%		 1.41 - - - 1.57 -0.43
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

MetaVia Inc.

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

545 Concord Avenue, Cambridge, MA, United States, 02138

857 702 9600

https://www.metaviatx.com

8

Name Title Year Born
Mr. Hyung Heon Kim CEO, President & Director 1977
Mr. Marshall H. Woodworth Chief Financial Officer 1958
Dr. Mi-Kyung Kim Chief Scientific Officer NA
Mr. Robert Homolka Senior Vice President of Clinical Operations NA
Dr. W. Christopher Fang M.D. Consulting Chief Medical Officer & Advisor NA
Mr. Michael C. Pine Senior Vice President of Business Development Advisor 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…